NCT01610947View on ClinicalTrials.gov

Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity

NACompletedINTERVENTIONAL
Enrollment

398

Participants

Timeline

Start Date

May 14, 2012

Primary Completion Date

October 18, 2018

Study Completion Date

October 18, 2018

Conditions
Spondyloarthritis
Interventions
DRUG

Adalimumab, Etanercept, Golimumab or infliximab

Continuation of usual treatment with fixed intervals according to standard recommendations

DRUG

Adalimumab, Etanercept, Golimumab or infliximab

Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol

Trial Locations (1)

34295

Lapeyronie Hospital, Montpellier

All Listed Sponsors
lead

University Hospital, Montpellier

OTHER

NCT01610947 - Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity | Biotech Hunter | Biotech Hunter